PubRank

A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial ID NCT01375842

PubWeight™ 77.14‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01375842

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014 12.00
2 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 10.49
3 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
4 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
5 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
6 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
7 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
8 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
9 Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol 2016 1.30
10 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
11 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
12 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
13 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
14 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
15 Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015 1.11
16 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
17 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
18 Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med 2015 1.04
19 Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 2012 1.03
20 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
21 Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015 0.99
22 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
23 Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016 0.95
24 Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev 2016 0.90
25 Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol 2015 0.89
26 Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015 0.89
27 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
28 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
29 Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016 0.87
30 Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 2015 0.86
31 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
32 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
33 The tumor microenvironment in esophageal cancer. Oncogene 2016 0.83
34 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
35 Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016 0.83
36 Current progress in immunotherapy for pancreatic cancer. Cancer Lett 2015 0.83
37 The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol 2016 0.83
38 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
39 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
40 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
41 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
42 The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016 0.80
43 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
44 Shedding light on the molecular determinants of response to anti-PD-1 therapy. Transl Lung Cancer Res 2015 0.79
45 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
46 New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res 2015 0.78
47 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
48 Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol 2016 0.78
49 The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel) 2016 0.77
50 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
51 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
52 Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon? Cancers (Basel) 2014 0.77
53 Future perspectives in cancer immunotherapy. Ann Transl Med 2016 0.77
54 Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol 2016 0.77
55 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
56 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
57 Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. J Mol Med (Berl) 2015 0.75
58 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
59 Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics 2015 0.75
60 Novel therapy for advanced gastric cancer. World J Gastrointest Oncol 2015 0.75
61 Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med 2016 0.75
Next 100